DRL-17822
Oncology
Phase 2Active
Key Facts
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories is a vertically integrated pharmaceutical company with capabilities spanning drug discovery, development, manufacturing, and commercialization. The company has built a strong portfolio of generic drugs, particularly in the US market, while also investing in complex generics, biosimilars, and proprietary drug development. With manufacturing facilities across multiple countries and a global workforce, Dr. Reddy's continues to expand its market presence through strategic partnerships, acquisitions, and new product launches. The company is publicly traded on both Indian stock exchanges and NASDAQ, reflecting its status as a major player in the global pharmaceutical industry.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Mvasi (bevacizumab biosimilar) | Viatris | Approved |
| Biosimilar Portfolio | Zydus Lifesciences | Various |
| therascreen Solid Tumor | Qiagen | Commercial |
| GBR 830 | Glenmark Pharmaceuticals | Phase 1 |
| Bevacizumab Biosimilar | Glenmark Pharmaceuticals | Approved |
| Biosimilar (Bevacizumab) | Ipca Laboratories | Development |
| LockBody Platform Assets | Centessa Pharmaceuticals | Pre-clinical |
| Everolimus | Amneal Pharmaceuticals | Approved |
| Lenalidomide (Revlimid generic) | Amneal Pharmaceuticals | Approved |
| Alymsys (bevacizumab-maly) | Amneal Pharmaceuticals | Approved |
| Pemrydi RTU | Amneal Pharmaceuticals | Approved |
| Focinez | Amneal Pharmaceuticals | Approved |